Restricted implants indicated for maintenance of opioid dependency.
Titan Pharmaceuticals and AllianceRx Walgreens Prime recently announced a partnership that will increase patient access to opioid-dependence management implant Probuphine.
Only available through a the restricted Probuphine REMS program, the new partnership is expected to increase patient accessibility.
“AllianceRx Walgreens Prime has excellent relationships with third-party payors and a network of fulfillment sites that spans the entire country,” says Dane Hallberg, Titan’s chief commercial officer. “Its broad reach will significantly improve the ability of OUD patients to gain access to long-term maintenance treatment with Probuphine."
Trending: Avoiding Pharmacist Burnout
Regarding treatment, Alliance Rx Walgreens’ vice president of pharmacy services Tracey James says the most effective treatment is the combination of counseling and medication-assisted treatment.
Probuphine (buprenorphine, Titan Pharmaceuticals)
Indications: Maintenance of opioid dependence in patients with sustained prolonged clinical stability on low-to-moderate doses of transmucosal buprenorphine-containing product
Dosage: Prescription use limited under Drug Addiction Treatment Act
Contraindications: Hypersensitivity to buprenorphine or any other ingredients in Probuphine
Warnings: Insertion and removal may result in implant migration, protrusion, expulsion, and nerve damage